Clinical trial
Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)
NCT00154271 is registered in ClinicalTrials.gov with Novartis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)
- Lead sponsor
- Novartis
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 31, 2004
- Completion date
- June 30, 2005
- Enrollment
- 1,677 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.